Scientists are exploring whether a tiny molecule could temporarily stop the production of sperm without permanently affecting fertility. A research team at Cornell University is targeting a specific stage of meiosis, which is the specialised form of cell division involved in producing sperm.

Using a compound called JQ1, the researchers were able to disrupt sperm development in mice and then observe the process returning after the treatment stopped. While JQ1 itself isn鈥檛 being developed as a contraceptive for people, the research is being used to test whether targeting this stage of sperm production can lead to a new type of non-hormonal male contraceptive.

It puts a much more precise form of biotechnology at the centre of male contraception, with the research testing whether fertility can be paused without permanently changing the underlying biological process. If that approach can eventually be turned into a safe treatment, it could give men another contraceptive option that is temporary, reversible and doesn鈥檛 rely on a permanent procedure.

Why Does Male Contraception Need A New Approach?

There are still limited options available to men with regard to contraception. Condoms are temporary but require single use, while vasectomies are serious surgical procedures intended to be permanent (even though they can, normally, be reversed). Hormonal approaches have also faced challenges around side effects and the practicalities of taking them consistently.

An approach that could temporarily switch sperm production off and then allow it to return could address some of these limitations. Instead of relying on a barrier during sexual intercourse or making permanent changes to fertility, the idea is to give men more control over when their fertility is active. Something which, in turn, would also have ramifications for women and the way in which they鈥檙e expected to use contraception. If there are more high-quality contraceptive options for men, perhaps the onus will no longer be entirely on women.

That鈥檚 why the Cornell research goes beyond finding another way to interrupt sperm production. It is testing whether a precise molecular intervention could eventually become a controllable form of contraception that may be used by the general public.

Why Is Male Birth Control So Difficult To Develop?

Sperm production is a continuous process, with cells developing from stem cells in the testes before moving through several stages to become mature sperm. Each stage has to happen properly, leaving the scientists with very little room for error when they are trying to control fertility.

That means researchers need to interrupt sperm production without damaging the cells that are responsible for starting it later again. The Cornell team avoided targeting stem cells that continually produce new sperm because damaging them could cause permanent infertility.

Instead, the researchers looked further along the process, aiming to interrupt sperm development while leaving those stem cells intact. It鈥檚 a bit like stopping a production line halfway through rather than switching the whole factory off.

How Does This Technology Work?

The compound used in the Cornell study is the JQ1, a small molecule that interferes with a protein called bromodomain testis-specific protein, or BRDT. Rather than developing JQ1 as a contraceptive itself, the researchers used the compound to test whether BRDT could be used as a target for controlling sperm production.

In this study, the male mice received JQ1 for three weeks, during which the sperm production stopped. Once the treatment ended, sperm production returned within six weeks and the mice were able to reproduce, giving the researchers evidence that targeting this process doesn鈥檛 necessarily have to mean permanently affecting fertility.

What Would This Look Like In Practice?

It鈥檚 too early to know what a contraceptive based on this approach would actually look like, since the research has only been carried out on mice. The researchers still need to identify targets that can produce the same effect safely, as well as work out how a future treatment could be delivered and how long its effects could last.

If researchers can overcome those challenges, this approach could give men another option beyond condoms, vasectomies and the other hormonal methods that are currently being researched.

There is still a long way to go before any of this could actually become another contraception method. Even so, this research is a good sign for the future of male fertility, and it shows how biotechnology could be used to influence fertility in a temporary and controlled way.

This is just another way in which complex biotechnology and medical technology has the potential to have very real-world ramifications that could improve people鈥檚 lives.

The post 鈦燱hat If Male Birth Control Worked Like A Switch? Scientists Are Finding New Ways To Control Fertility appeared first on 91探花.

We normally think of DNA as the thing carrying the instructions for life, sitting inside our cells and helping determine how our bodies work. It鈥檚 probably not the first thing you鈥檇 expect to find in a piece of computer hardware, unless your biology teacher had a particularly ambitious lesson plan.

Now, researchers at Penn State are asking whether DNA could have another job entirely: helping computers store information. They鈥檝e developed a small memory device that combines synthetic DNA with a semiconductor called perovskite, and the results show that biology could have a place in future electronics.

It鈥檚 still a long way from completely replacing the storage in your laptop, but it鈥檚 a pretty strange idea to get your head around.

Why Are Scientists Putting DNA Into Computers?

DNA and computer hardware seem like they should stay in completely separate worlds. One is associated with genetics and the other with processors, storage drives and the collection of cables behind your desk that nobody wants to untangle.

The reason scientists are interested in DNA is its insane ability to hold information in a very small space. Penn State researchers says a single gram of DNA could theoretically hold about 215 million gigabytes of data.

The challenge is working out how to make DNA useful in an electronic device. Rather than trying to replace a computer drive with DNA, the researchers have been experimenting with how synthetic DNA can work alongside other materials to create a new type of memory.

So How Does DNA Become Computer Memory?

The researchers used short pieces of synthetic DNA that were specially designed for the experiment, rather than taking DNA from a living person. They added tiny silver particles to the DNA and combined it with a thin layer of perovskite, a material that has also attracted attention for its potential in solar technology.

Together, these materials form a device called a memristor. The name sounds more complicated than the basic idea, which is that the device can change between different electrical states and remember which state it was in.

That means it can store information rather than simply allowing electricity to pass through it. The researchers found that their device could operate using less than 0.1 volts and could keep its memory behaviour for more than six weeks under normal room conditions. It also continued working at temperatures approaching 250 degrees Fahrenheit or 121 degrees Celsius.

DNA isn鈥檛 being used because scientists think computers should become biological. Instead, its structure can help the electronic materials behave in useful ways.

Could DNA Actually Make Computers More Efficient?

The Penn State team says its device uses 100 times less power than traditional storage devices while providing higher storage capacity. The researchers are interested in the technology for future electronics that need to handle large amounts of information without using a huge amount of energy.

That doesn鈥檛 mean a DNA memory stick is about to replace your SSD. The device is still a prototype, and there are plenty of practical questions before anything like this could become part of everyday technology.

For data centres and other large computing systems, where thousands of devices can be running at the same time, reducing the amount of electricity each one needs could add up quickly. As computers continue handling more data, finding ways to make memory use less energy could be as important as making the hardware faster.

Could Biology Change How We Build Computers?

For decades, improving computers has meant making electronic components smaller, faster and more efficient. Researchers are now looking at whether different materials could help push things further, especially as the amount of data computers need to handle keeps growing.

The Penn State device doesn鈥檛 prove that DNA will replace silicon, and it definitely doesn鈥檛 mean our laptops are about to become miniature biology experiments. What it does show, however, is that synthetic DNA can be combined with electronic materials to create a working memory device with some unusual properties. It also shows that there鈥檚 still a lot modern technology can learn from biology.

There鈥檚 still a lot to figure out before this could become useful outside a laboratory, but I like the fact that the researchers aren鈥檛 trying to make the same old computer hardware a little faster. They鈥檙e looking somewhere completely different for the answer.

We鈥檝e spent so long teaching computers to imitate parts of the human brain, so it was just a matter of time before we started taking a few ideas from biology too. Turns out, it may be that DNA could be in for quite the career change.

The post Scientists Just Gave DNA A New Job: Could Biology Be The Future Of Data Storage? appeared first on 91探花.

Our bodies are constantly throwing off subtle clues about what鈥檚 going on beneath the surface, but modern medtech still struggles to read a lot of them. Biomarkers are measurable biological signals, like specific proteins, hormones or genetic material, that give doctors a better idea of what is actually inside the body.

As someone currently being 鈥渢reated鈥� for endometriosis, I know firsthand how strange it feels to live with a condition that impacts your everyday life when there is currently no cure for it. But endometriosis is just one example of why researchers are looking for better ways to understand women鈥檚 health. Biomarkers could help doctors track diseases, see if treatments are working and potentially spot changes earlier.

So, What Is A Biomarker?

Biomarkers are measurable clues found inside the body. Scientists can look for these biological signals in things like blood, urine or tissue.

They can be used to monitor existing illness, see how disease changes over time or check whether someone is responding to a particular treatment. These signals can reveal more about what鈥檚 happening inside a body, but the challenge is making sure they actually tell doctors something useful.

Finding a biological signal linked to a condition doesn鈥檛 automatically make it a reliable medical test. Researchers need to figure out how accurate and consistent it is before doctors can use it as part of routine care. A marker might show a connection to a disease in research without being accurate enough to diagnose that disease in an individual patient.

Could Biomarkers Help With Endometriosis?

The potential uses of biomarkers don鈥檛 necessarily end once a condition has been identified. Researchers are also interested in whether biological signals could help show how a disease is changing or how different patients respond to treatment.

That could eventually make treatment more personalised. Instead of looking only at symptoms and deciding whether something appears to be working, doctors could potentially have biological information to consider alongside them. For a condition like endometriosis, where symptoms and experiences can vary significantly between patients, having more information could make treatment decisions more informed.

We are still a long way from biomarkers being used this way as standard care. But, research into blood-based signals is already moving toward clinical testing, with a 2025 study reported by Nature investigating whether microRNA could be turned into a non-invasive diagnostic test for endometriosis.

Could Biomarkers Give Women More Hope?

There鈥檚 something reassuring about seeing researchers look for answers to questions that medicine still can鈥檛 fully answer. Biomarkers are still being tested and refined, but the possibility of finding measurable signs that can tell us more about conditions like endometriosis gives me hope that women鈥檚 healthcare can move beyond simply managing symptoms. After all, we can鈥檛 expect to solve problems until we鈥檙e asking the right questions.

I don鈥檛 expect a blood test to magically change everything overnight. But knowing that research is moving towards more precise ways of understanding what鈥檚 happening inside our bodies makes the future feel a little less uncertain. For anyone living with a condition that has no cure, that alone can mean a lot.

It is a reminder that even when medicine doesn鈥檛 have all the answers yet, researchers are still looking for them. And sometimes, knowing that the search is happening is enough to give women a little more hope for what comes next.

The post What Are Biomarkers And How Are They Transforming Women’s Health? appeared first on 91探花.

91探花 is excited to announce the winners of the 2026 HealthTech44 campaign, celebrating the most exciting and innovative businesses in health and medical technology this year.

Founded in 2016, 91探花 is the UK鈥檚 best-known and fastest-growing startup and tech news site. This聽is where decision-makers, investors and startups of all sizes and nature come to find out the latest developments and trends within the industry.

See The List

Top 44 鈥� See Here >>

Top 40 鈥� See Here >>

Top 30 鈥� See Here >>

Top 20 鈥� See Here >>

Top 10 鈥撀�See Here >>

Who Ranked Number 1? 鈥撀�See Here聽>>

Feedback From The Judges

One of the most encouraging aspects of judging this year鈥檚 HealthTech44 competition was seeing how many founders were thinking beyond the technology itself. The strongest entries combined innovative technology with a clear understanding of the clinical problem they were solving and a credible pathway to bringing that solution into practice. That combination of innovation, evidence and a clear route to adoption made this an exceptionally strong field and was a reminder of just how much high-quality innovation is taking place across the sector. Congratulations to everyone who took part, and particularly to this year鈥檚 winners.

Head Judge 2026

Dr. Stuart Grant, Founder of

Judging this field reinforced how quickly healthtech is moving from point solutions toward trusted clinical infrastructure. The strongest entries did more than present an interesting idea: they addressed a meaningful care or workflow problem, showed evidence of execution, and designed around the realities of clinicians, patients, regulation, and deployment. I was particularly drawn to companies combining clinical usefulness with measurable traction, explainable AI, strong data foundations, or devices capable of improving access outside traditional care settings.

I deliberately did not rank companies based only on size, valuation, or fundraising. Several early-stage teams scored well because the problem was urgent, the founder insight was authentic, and the pathway to validation was credible. The main gap across weaker entries was not ambition, but proof鈥攃lear outcomes, regulatory strategy, differentiation, and evidence that the solution can work consistently in real healthcare environments.

Jeremy Lawson, Founder and CEO of Salynt Inc.

As an independent virtual CISO with a background in risk management, cybersecurity, and regulatory compliance, I prefer facts over marketing claims. For 91探花’s HealthTech44 2026, I ranked the submissions on five evidence-based dimensions: stated security maturity, AI claim substantiation, clinical validity, patient impact, and the team’s credibility. Companies that scored higher had provided named certifications, published benchmarks, regulatory clearance, quantified outcomes, and experienced clinical leaders named in their submission. By comparison, entries with visible AI instructions, placeholder content, or contradictory claims were disqualified, and submissions that were primarily unsubstantiated product marketing ranked poorly with me.

Kayne McGladrey, Independent Virtual CISO

The list of startups are amongst the top health tech companies in the world tackling the most challenging health problems with their impact able to improve healthcare outcomes around the world. With the current theme of AI helping to deliver great outcomes, I am glad to see many healthtech companies utilising and being AI-first.

Samuel Okwuada, Founder and CEO of Remedial Health

Judging this year’s HealthTech competition was an inspiring experience. The quality of the submissions reflected the incredible innovation happening across the healthcare sector, with companies tackling real-world challenges through technology. From advancements in remote patient monitoring to AI-driven diagnostics and neurological care, these solutions demonstrated both technical excellence and a clear understanding of the needs of patients and healthcare professionals. What stood out most was the focus on creating accessible, scalable technologies with the potential to make a meaningful impact. It was encouraging to see such a high standard of innovation, and I look forward to seeing how these companies continue to shape the future of healthcare.聽

Laliq Schuman, Reporter and SEO Executive at 91探花聽

Thank You To Our Judges

Head Judge 2026

Dr. Stuart Grant, Founder of

Dr. Stuart Grant is the Founder of Archetype MedTech, where he provides product development leadership to founders, investors, and MedTech companies, bringing innovative medical technologies to market.

Alongside Archetype, Stuart is Co-Founder of C-True Surgical, Product Development Leadership Advisor to the Science and Engineering Health Technologies Alliance (SEHTA) and a Product Development Mentor with the NHS Clinical Entrepreneur Programme. His work spans the UK, Europe, the US and APAC, including Australia, China, and India.

Before founding Archetype, Stuart spent 25 years with Johnson & Johnson MedTech, where he established and led the company’s Shanghai R&D Centre of Excellence. He is a Chartered Engineer, a Fellow of the Institution of Mechanical Engineers, holds a PhD in Medical Device Technology and Innovation, is a named inventor on multiple US medical device patents and is a regular speaker, mentor and contributor across the global MedTech sector.

Read more about Dr. Stuart Grant and what he’s looking out for in HealthTech44 entrants here.

Aline G贸mez-Acebo Finat, CEO at ENIAX

Aline Gomez-Acebo Finat is a prominent tech operator, angel investor, and ecosystem builder specializing in deep tech, digital health, and venture capital. As the CEO of ENIAX, she scales a healthtech platform utilizing machine learning and natural language processing to manage data for nearly 100 million patients across 8 countries.

Committed to bridging the venture funding gap, she is also the Co-Founder of Calafia Iberia, the region’s first women-led angel investment syndicate. An Adjunct Professor at IE Business School with executive credentials from MIT, Stanford, and Harvard, Aline has received numerous awards like Top 100 Female Leader and EPIC award for her sustainability efforts in business.

Jeremy Lawson, Founder and CEO of Salynt Inc.

Jeremy Lawson is the Founder and CEO of Salynt Inc., a healthcare AI company developing advanced neuroimaging and clinical decision-support technologies that help clinicians better understand and treat complex neurological conditions. With over a decade of experience in artificial intelligence, data science, and technology innovation across the Department of Defense and Intelligence Community, he understands the intersection of healthcare, technology, and commercialization. Jeremy holds a Master’s in Data Science from The George Washington University and a Bachelor’s in Mathematics from Jackson State University.

Beyond his professional work, Jeremy is committed to mentorship, education, and community impact. He is a member of The National Alliance for Doctoral Studies in the Mathematical Sciences and previously served as President of the Maryland Black Caucus Foundation and Vice President of the International Black Firefighters Museum. He is passionate about empowering the next generation of innovators while advancing technologies that improve patient outcomes and clinical decision-making.

Jeremy enjoys cooking, playing the piano, traveling, and watching football in his spare time.

Kayne McGladrey, Independent Virtual CISO

Kayne McGladrey is an independent virtual CISO who helps SMBs and mid-market firms navigate compliance, AI regulation and cyber risk. Author of the upcoming book “Cyber Risk is a Myth,” and ranked number one globally for his cybersecurity and risk management expertise, Kayne bridges technical security with business outcomes.

Oren Hershkovitz, Chief Executive Officer and Enlivex

Oren Hershkovitz is the CEO at Enlivex (Nasdaq: ENLV), a quality longevity company advancing Allocetra, a clinical-stage immunotherapy targeting age-related osteoarthritis, alongside a prediction markets treasury strategy built around the RAIN protocol.

In 2025 the company reported $1.23 billion in net profit and received FDA clearance for a Phase 2b clinical trial in the same week. Oren is a pharmaceutical executive with over 20 years of experience leading clinical programs from early discovery through Phase III trials and has overseen more than $200 million in financing throughout his career. He holds a PhD in Immunology with distinction from Ben-Gurion University of the Negev.

Prior to joining Enlivex in 2019, Oren served as General Manager of OPKO Biologics, where he led the late-stage clinical development of Ngenla, a long-acting growth hormone co-developed with Pfizer that is now approved in more than 40 countries, including the United States, the European Union and Japan.

Samuel Okwuada, Founder and CEO of Remedial Health

Samuel Okwuada is the Founder and Chief Executive Officer of Remedial Health, a healthcare technology company focused on optimizing the pharmaceutical supply chain in Africa. Educated as a pharmacist with a Master’s degree in Pharmacy from the University of East Anglia, UK; he is also a self-taught software engineer who initially began writing code at age 14.

During his university studies, Okwuada established a track record as a serial entrepreneur by founding 3 distinct startup companies and successfully completing 2 corporate exits. Through his leadership at Remedial Health, he builds direct-to-retail distribution networks for medical and non-medical consumables to improve inventory affordability for independent pharmacies across the African continent. His platform directly addresses regional supply shortages and pricing inefficiencies within the traditional medical distribution model.

Okwuada remains focused on leveraging his dual expertise in software engineering and clinical pharmacy to modernize medicine access and healthcare logistics.

Laliq Schuman, Reporter and SEO Executive at 91探花

Laliq is an SEO Executive with experience writing optimised content for a wide range of clients. She specialises in creating SEO-driven blogs and on-site content that aligns with both search intent and brand voice. With a client base spanning multiple industries, Laliq brings a broad knowledge of tech and consumer-focused topics to her work. Her exposure to innovation-driven sectors has sparked a particular interest in how technology can support and improve healthcare.

The post Announced! 91探花’s HealthTech44 Winners 2026… appeared first on 91探花.

Co-Founder & CEO: Vasili Razhnou

奥别产蝉颈迟别:听

About MEDvidi

MEDvidi emerged from traditional offline clinics in San Francisco and Miami in 2019, transitioning to a custom telehealth platform in 2020. Co-founders Vasili Razhnou and Alex Kulitski combined healthcare operations and technology expertise to build a platform that connects patients with licensed therapists and prescribing clinicians in one coordinated care model – making high-quality, affordable mental health care accessible across the US for ADHD, anxiety, and depression.

The biggest problem in healthcare today is provider capacity. Millions of Americans cannot access mental health care. The reason is that psychiatrists are fully booked with routine follow-up visits and administrative tasks, leaving no capacity for new patients. MEDvidi built its AI directly around that bottleneck. The AI Chart Generator transcribes visits in real time, updating documentation every 60 seconds and cutting charting time by 10x.

The AI Chart Reviewer monitors 100 percent of clinical encounters for protocol adherence, reducing review time by 80 percent while handling ID verification, drug-seeking detection, and guideline compliance. An AI Receptionist manages rescheduling, gathers prescription-related updates from patients, and feeds everything back into clinical workflows. By removing that friction, MEDvidi enables clinicians to see up to 10 times more patients.

Unlike other AI health tools trained on non-specific medical data, MEDvidi AI is trained on 130,000 real psychiatric visits. It is purpose-built for psychiatric workflows, regulations, and controlled-substance requirements. It works as a clinical verification layer, grounded in evidence-based guidelines and a proprietary dataset of real historical visits, ensuring every prescription aligns with standards and providing regulators with transparent oversight. The AI does not make independent decisions. The view at MEDvidi is blunt: AI in medicine should solve bottlenecks in doctors’ workflows and make clinicians more capable, not replace them.

Want to find out what 91探花 can do for your business?

Contact us today.

The post 36. MEDvidi appeared first on 91探花.

Founder & CEO: Bilal Farooqi

Website:

About Sunny Health AI

Sunny Health AI is an AI-powered healthcare navigation platform that acts as a virtual healthcare concierge for employees and their families. The platform helps users understand their insurance benefits, locate in-network providers, book appointments, answer coverage questions, and coordinate follow-up care through conversational AI. Its primary customers are employers, particularly startups, looking to improve employee healthcare access while reducing HR workload and unnecessary healthcare spending.

Want to find out what 91探花 can do for your business?

Contact us today.

The post 40. Sunny Health AI appeared first on 91探花.

颁辞-贵辞耻苍诲别谤蝉:听 Elena Ikonomovska (CEO) and Andrii Yasinetsky (CTO)

奥别产蝉颈迟别:听

About Diadia Health聽

Diadia Health is a diagnostic reasoning platform built for clinicians who want AI they can verify, not just trust. Every AI tool that touches patient care makes claims. Diadia is the platform built to prove them: every clinical claim it generates is sorted into one of three tiers, Supported by Science, Plausible, or Unsupported, so clinicians see exactly why the AI reached its conclusion, not only what it concluded.

Diadia was founded in 2023 by Elena Ikonomovska, PhD, and Andrii Yasinetsky to solve a problem the two of them saw across precision, functional, and longevity medicine. Elena spent over 20 years in applied AI and machine learning. Andrii spent his career building production AI systems and agent infrastructure, including roles at Uber and Google. Together they set out to give clinicians an AI tool built specifically for how they practice, one they could verify rather than simply trust.

Clinicians are drowning in multi-omic data, labs, metabolic panels, genetics, and gut health among others, with no way to read it all as one connected picture. Diadia analyzes that data as a single biological system rather than a set of disconnected reports, surfacing root cause relationships that would not appear if each test were read on its own. Every medical claim the platform generates is checked against a reasoning graph built on more than 310,000 peer-reviewed papers and over 700,000 genetic variants, then classified through that three-tier verdict system before it ever reaches a clinician.

The hardest problem Elena and Andrii had to solve was not building an AI that sounded confident. It was building one that could show its work. In an independent study, Diadia tested 3,035 medical claims across 36 patients against four leading AI models. The models agreed with each other no better than random chance on identical patient data, a cross-model Fleiss kappa of negative 0.045, the exact bottleneck Diadia was built to close. Diadia classified 67.1 percent of its own claims as Supported by Science, 30.2 percent as Plausible, and 2.7 percent as Unsupported, giving clinicians a transparent, auditable answer instead of a black box.

The platform now runs end-to-end around the patient visit, covering pre-visit diagnostic prep, in-visit multi-omic analysis, and post-visit branded patient materials, all trained on the clinical style of each individual clinician. Clinics using Diadia have cut chart review time for complex cases down substantially, based on Diadia internal modeling, freeing clinicians to see more patients without adding staff or sacrificing the personalization their patients pay for.

Since launch, Diadia has been recognized twice by 91探花 alone, Top 50 Women in Startups and Tech and AITech45, plus wins from Femtech World and 100 Women in AI, building a track record of independent validation to match its own verification approach.

Diadia is not trying to replace clinical judgment. It is focused on making that judgment easier to trust, easier to scale, and easier to prove.

Want to find out what 91探花 can do for your business?

Contact us today.

The post 14. Diadia Health appeared first on 91探花.

Founder: Ahmed Hessam

Website:

About OSAA INNOVATION

OSAA Innovation is a Danish medtech company revolutionising IV treatment solutions in healthcare. Founded in 2016, OSAA Innovation aims to address the stigma surrounding patients undergoing IV treatments and as well the overall lack of progressive technological solutions within the IV healthcare industry.

By combining enhanced user-focused approach, connectivity and smart mechanical engineering, OSAA Innovation aims to empower healthcare professionals with user-friendly connected products to improve patients’ healthcare journeys and improve IV treatment results for more than 90% of hospitalised patients, receiving some form of IV therapy.

Today, OSAA Innovation maintains a distribution network across Scandinavia, Australia, Saudi Arabia, and Poland, and meets the needs of the patients and healthcare institutions in different regions.

The company is also a multi-award-winning industry leader, recently securing the Gold Winner Accolade from the Australian Good Design Awards and the German Design Award.

Why OSAA Innovation Stands Out:
By bridging the 97% healthcare data gap through real-time remote monitoring and connectivity, as well as restoring mobility to patients, OSAA directly addresses clinical burnout, reduces fall risks, and enables the safe transition to home-based and alternative settings IV care.

Backed by global awards in design and healthcare, as well as rapidly expanding international footprint across Europe, Asia-Pacific, and the Middle East, OSAA Innovation moves the needle in infusion therapy and stands out as a true category creator driving the next generation of smart healthcare delivery.

Want to find out what 91探花 can do for your business?

Contact us today.

The post 34. OSAA INNOVATION appeared first on 91探花.

Vice President: Antoine Pivron

奥别产蝉颈迟别:听

About Withings Health Solutions

Withings Health Solutions is the dedicated B2B division of Withings, a pioneer in connected health technology since 2008 ,with millions of users across more than 30 countries today. The organisation provides medical grade, clinically validated smart devices designed for remote patient monitoring, chronic disease management, and clinical research, with over 1 million patients monitored to date. The goal is to build a continuous bridge between individuals and their healthcare providers.

The journey began when the parent company introduced the first-ever connected scale in 2009, followed by continuous advancements in medical wearables, blood pressure monitors, sleep trackers, and non-invasive home health labs. The primary challenge addressed over the years involves shifting the healthcare system from a reactive model to a proactive, preventive approach.

Ensuring medical validation and clearing regulatory benchmarks such as FDA approval and CE marks across various global regions requires strict compliance and continuous investment. Additionally, the company overcame infrastructure demands by developing cellular connected tools that work out of the box, eliminating the need for complex user setup or smartphone dependencies for elderly or vulnerable patient groups.

The impact on the healthtech landscape has been substantial. By offering beautifully designed tools that patients actually want to use daily, the team achieves high retention and compliance rates. This continuous stream of real world data allows clinicians to monitor conditions like hypertension, heart failure, and diabetes seamlessly.

Instead of relying on sporadic in clinic readings, care teams receive precise, regular insights to catch health issues early, adjust treatment plans, and reduce emergency room visits. The solutions empower medical institutions, payers, and research bodies to deploy scalable, efficient care programs that save costs and improve life outcomes globally.

Want to find out what 91探花 can do for your business?

Contact us today.

The post 37. Withings Health Solutions appeared first on 91探花.

Founder: Dr. Peter FitzGerald

奥别产蝉颈迟别:听

About Randox Health

Randox Health develops diagnostic solutions for hospitals, clinical, research and molecular labs, food testing, forensic toxicology, veterinary labs and life sciences. It develops, manufactures and markets reagents and equipment for laboratory medicine, with a distribution network of 145 countries. Randox is the biggest COVID-19 testing provider in the UK and Ireland. Randox manufactures more clinical diagnostic products than any other company in the world. It invests around 25% of profits into R&D, and almost a quarter of its staff are research scientists and engineers.

Beginning with a team of six employees, the company now has 1500 employees around the world. It moved into the Randox Science Park, a 45-acre R&D and manufacturing site housed on the former Massereene Barracks in 2019. It has also recently invested 鈧�25m in developing a site in Dungloe, Donegal. Randox Teoranta aims to create more than 470 jobs in research, engineering and life sciences by 2020.

Randox鈥檚 range of reagents covers many different techniques such as colorimetric, UV and immunoturbidimetric methods. As a result of heavy investment in R&D, Randox鈥檚 portfolio has grown to provide a wider variety of reagents.

Want to find out what 91探花 can do for your business?

Contact us today.

The post 41. Randox Health appeared first on 91探花.